Pinned Tweet
A heartfelt thank you from KlinPharm to Prof. Stefan Endres for a lifetime of leadership 🥂@LMU_Muenchen @Harvard_Imm
LMU Clinical Pharmacology retweeted
Welcome, Prof. Matthias Tschöp! The internationally renowned physician and medical researcher is now President of Ludwig Maximilian University München (LMU). ✨
Another year of science, solidarity and 12 °C swims at the i-Target: Immunotargeting of Cancer annual retreat. @Baldauf_Lab @LabTheurich @buchnerlab_tum @hopfnerlab @skimhellmuth @harvardmed @LMU_Muenchen #iTarget
LMU Clinical Pharmacology retweeted
#InterferonPower! Thrilled for our latest work @CellCellPress! With @dfrboehmer, we dug into tons of papers & created what we hope will be a go-to resource for immunologists & non-immunologist about type I, II, III (& IV😉) #interferons! Free link 👉 authors.elsevier.com/a/1leKG…
LMU Clinical Pharmacology retweeted
Deep Immune Phenotyping Reveals Distinct Immunopathogenesis in Checkpoint Inhibitor–Induced Colitis Compared with Ulcerative Colitis: brnw.ch/21wUjA3
LMU Clinical Pharmacology retweeted
Rebalancing the Immune System to Fight Type 1 Diabetes 🔬
👉 t1p.de/n6s0g
Can we go beyond symptom management in T1D treatment? A new collaborative study by #HelmholtzMunich, the German Center for Diabetes Research, and the Goethe University Frankfurt offers promising insights.
Researchers investigated vidofludimus calcium, a next-generation immunomodulatory drug currently in phase 3 trials for multiple sclerosis. The drug targets DHODH, a key enzyme involved in immune cell metabolism and essential for the survival of overactive immune cells.
In preclinical models, the treatment:
🔹Reduced activation of harmful T cells
🔹Increased protective regulatory T cells (Tregs)
🔹Delayed the onset of autoimmune diabetes
🗨️ “With this publication we discover for the first time that inhibiting the enzyme DHODH fosters immune-protective Tregs during islet autoimmunity and delays the progression to overt T1D in pre-clinical models.”
– Prof. Carolin Daniel, senior author of the study.
💡These findings represent a significant step toward immune-based therapies for Type 1 Diabetes – shifting the focus from managing symptoms to preventing disease progression.
🔗 To the original publication: t1p.de/9c20z
@DanielLabMunich @DiabResearch @goetheuni
#Type1Diabetes #Immunology #DiabetesResearch #ImmuneTherapy
Two new doctors on the loose! Huge congratulations to Emanuele Carlini and Jan Gärtig 🥂#PhD
9
350
Great to see our new study on a vulnerable phase in HCC immunotherapy highlighted. Thank you @Erman_Akkus, and thanks to all collaborators!
Can't be stopped 🏃⚡️- team #KlinPharm at the B2Run in Munich's Olympiapark #B2Run2025
3
325
Big congrats to Kathrin Gabriel #Koboldlab on her paper "Long-term consequences of cancer therapy: cognitive impairment following CAR T cell therapy" - out now 💥
nature.com/articles/s41392-0…
4
215
LMU Clinical Pharmacology retweeted
Now online! Pseudouridine RNA avoids immune detection through impaired endolysosomal processing and TLR engagement dlvr.it/TLfrWv
🥳Amazing publication from the @hornung_lab, in collab. with the @CarellThomas lab, on the innate immune system: how modified RNA tricks the immune system. Big shout-out to the two first authors, @BeroutiMarleen and Mirko Wagner!
sciencedirect.com/science/ar…
lmu.de/en/newsroom/news-over…
2
287
LMU Clinical Pharmacology retweeted
Metabolites as agents and targets for cancer immunotherapy nature.com/articles/s41573-0…
This new Review discusses the role of metabolic pathways in cancer and immune cells in shaping the tumour microenvironment, and how they can be targeted to improve anticancer immune responses
LMU Clinical Pharmacology retweeted
Very excited to share our review on "Metabolites as agents and targets for cancer immunotherapy" in @NatRevDrugDisc! read it here: rdcu.be/etAMD
@SpringerNature @KlinPharm
LMU Clinical Pharmacology retweeted
Inspired by @OliveiraMann, @BekereIndra, and Veronika Merold’s article in @MolecularCell, my latest cover art illustrates OAS2’s unique requirement for Golgi membrane localization, essential for restricting viruses!
@TU_Muenchen
#sciart ⌬ #research ⌬ #chemistry
I’m very excited to share our first preprint “Structural Basis for OAS2 Regulation and its Antiviral Function” from my postdoc together with Veronika Merold (Vroni) from NTase lab with @OliveiraMann biorxiv.org/content/10.1101/…
Predictive value of preclinical models for CAR-T cell therapy clinical trials: a systematic review and meta-analysis jitc.bmj.com/content/13/6/e0…
2
152
LMU Clinical Pharmacology retweeted
📢Call for Reading:
*Role and Potential of Different #T Helper #Cell Subsets in Adoptive Cell Therapy*
🙌Citations: 28
👨🔬by David Andreu-Sanz and Sebastian Kobold
#OpenAccess 🔓mdpi.com/2072-6694/15/6/1650
🗞️🗞️🗞️König and Schnurr Lab in @MolecularCell @LM_Koenig @OliveiraMann @BekereIndra, Veronika Merold and @PichlmairL Structural basis for OAS2 regulation and its antiviral function cell.com/molecular-cell/full…
3
224
LMU Clinical Pharmacology retweeted
Structural basis for OAS2 regulation and its antiviral function dlvr.it/TLBmgD
































